Protagonist Therapeutics, Inc. sees a big potential commercial opportunity for its oral gut-restricted α4β7-integrin antagonist PN-943 in ulcerative colitis (UC) and is pushing ahead with the Phase III development of a low dose formula, despite mixed Phase II data that underwhelmed investors.
The Phase II IDEAL study, evaluating PN-943 at two doses twice a day (450 mg and 150 mg) in patients with moderate-to-severe UC, missed the primary endpoint – the proportion of subjects achieving clinical remission at Week 12 at the